Brenton Taylor Sells 5,000 Shares of Inogen Inc (INGN) Stock

Inogen Inc (NASDAQ:INGN) EVP Brenton Taylor sold 5,000 shares of Inogen stock in a transaction that occurred on Friday, February 16th. The shares were sold at an average price of $125.06, for a total value of $625,300.00. Following the completion of the sale, the executive vice president now directly owns 38,982 shares in the company, valued at approximately $4,875,088.92. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Brenton Taylor also recently made the following trade(s):

  • On Wednesday, February 14th, Brenton Taylor sold 15,000 shares of Inogen stock. The shares were sold at an average price of $117.47, for a total value of $1,762,050.00.

Inogen Inc (INGN) opened at $126.84 on Wednesday. The firm has a market capitalization of $2,650.00, a P/E ratio of 88.70, a price-to-earnings-growth ratio of 4.05 and a beta of 1.02. Inogen Inc has a one year low of $67.34 and a one year high of $130.05.

INGN has been the topic of a number of recent research reports. Zacks Investment Research raised Inogen from a “hold” rating to a “buy” rating and set a $131.00 target price on the stock in a research report on Thursday, November 9th. BidaskClub raised Inogen from a “hold” rating to a “buy” rating in a research report on Saturday, February 10th. Finally, Leerink Swann reissued an “outperform” rating and issued a $120.00 target price (up previously from $115.00) on shares of Inogen in a research report on Wednesday, November 8th. Two research analysts have rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus target price of $103.71.

Hedge funds have recently bought and sold shares of the business. Parametric Portfolio Associates LLC grew its stake in Inogen by 63.6% in the second quarter. Parametric Portfolio Associates LLC now owns 45,969 shares of the medical technology company’s stock valued at $4,386,000 after purchasing an additional 17,867 shares in the last quarter. California Public Employees Retirement System grew its stake in Inogen by 31.2% in the third quarter. California Public Employees Retirement System now owns 26,498 shares of the medical technology company’s stock valued at $2,520,000 after purchasing an additional 6,298 shares in the last quarter. Verition Fund Management LLC bought a new position in Inogen in the second quarter valued at approximately $280,000. Quantbot Technologies LP grew its stake in Inogen by 74.1% in the third quarter. Quantbot Technologies LP now owns 9,665 shares of the medical technology company’s stock valued at $919,000 after purchasing an additional 4,112 shares in the last quarter. Finally, Allianz Asset Management GmbH grew its stake in Inogen by 3.8% in the third quarter. Allianz Asset Management GmbH now owns 40,629 shares of the medical technology company’s stock valued at $3,864,000 after purchasing an additional 1,490 shares in the last quarter.

TRADEMARK VIOLATION WARNING: “Brenton Taylor Sells 5,000 Shares of Inogen Inc (INGN) Stock” was published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this piece of content on another domain, it was illegally copied and republished in violation of international copyright & trademark law. The legal version of this piece of content can be read at https://www.dispatchtribunal.com/2018/02/21/brenton-taylor-sells-5000-shares-of-inogen-inc-ingn-stock.html.

Inogen Company Profile

Inogen, Inc is a medical technology company. The Company develops, manufactures and markets portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. The Company’s Inogen One systems concentrate the air around the patient to offer a single source of supplemental oxygen anytime, anywhere with a portable device.

Insider Buying and Selling by Quarter for Inogen (NASDAQ:INGN)

Receive News & Ratings for Inogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inogen and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply